Trump Administration Weakens Drug Protections by Downgrading Medical Marijuana
Select a version of the text written from a presumed ideological perspective. This is not the original text, but a hypothetical version — how someone with that viewpoint might have phrased it. Tapping the current version again will return to the original or select cleaned version.
The Justice Department has reclassified state-licensed medical marijuana from Schedule I to Schedule III, undermining strong drug laws and easing restrictions despite ongoing concerns.
The Justice Department announced on Thursday the reclassification of state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This controversial change concedes to the demands of the marijuana lobby, acknowledging so-called medical uses of cannabis and reducing crucial regulatory barriers. The move will make it easier for businesses to profit and claim tax deductions, raising concerns about the influence of Big Cannabis.
Acting Attorney General Todd Blanche stated, "The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options." While the administration touts this as progress, many Americans worry that it signals a dangerous shift away from common-sense drug policy.
The reclassification does not legalize marijuana federally, but it does follow President Trump's December executive order, which directed the Justice Department to expedite the process. The administration is planning further reclassification efforts, with broader hearings scheduled for June, raising fears of even more erosion of federal drug protections.
Critics, such as Kevin Sabet of Smart Approaches to Marijuana, have rightly pointed out that the tax relief primarily benefits large cannabis companies and sends a confusing message about the risks of marijuana. While some supporters hail this as a major step, many believe it is a reckless move that prioritizes profits over public safety.